Objective: We performed an individual participant data (IPD) meta-analysis to calculate the recurrence risk of hypertensive disorders of pregnancy (HDP) and recurrence of individual hypertensive syndromes.
Introduction
Hypertensive disorders of pregnancy (HDP) are a common health problem and are the second most common cause of maternal death worldwide, with major intriguing regional differences worldwide. 1 They complicate approximately 2-8% of all pregnancies [2] [3] [4] and comprise gestational hypertension (GH), preeclampsia, superimposed preeclampsia, and HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome; in a varying percentage of cases, the disorders are related to intrauterine growth restriction. There is probably important heterogeneity in pathophysiologic and clinical phenotype between subgroups and individual women, with maternal endothelial dysfunction as a central phenomenon, caused by an excessive maternal response to placental material. Furthermore an HDP identifi es the woman who is at risk for cardiovascular disease later in life, probably because of shared risk factors and pathophysiologic evidence. 2, 4 HDP can also have a major psychologic impact on the woman and her family. 5 As such, counseling on recurrence of a hypertensive disease in a future pregnancy is important. Consequently, many studies have focused on the investigation of recurrence rates of HDP. Interpretation of these studies, however, is diffi cult because of many potential sources of bias, including patient selection and study methods. This causes every cohort to have a specifi c case mix of different clinical phenotypes and macroethnicities. Reported recurrence rates range from a few percent up to 65%. 6 Similarly, the performance of individualized risk prediction models has been disappointing because HDP have heterogeneous pathophysiologic characteristics. 7 In addition, suboptimal size and generalizability of studies cause these prediction models to be unsatisfactory. 7 Recurrence rates of the individual syndromes of HDP in literature for preeclampsia can be found ranging up to 65% 6 and for HELLP syndrome can range from 2-3%. 8, 9 Recurrence of GH has not been explored in many studies. Delivering a small for gestational age (SGA) child recurs in approximately 24% of pregnancies. 10 Individual participant data (IPD) meta-analysis is new to prognostic research. 11 In contrast to conventional meta-analysis, it uses the IPD of the original studies, thus enlarging the study population and increasing statistical power to detect subtle relationships. In contrast to aggregated data meta-analysis, it permits synthesis at an individual level, which creates flexibility in choosing outcome and subgroups. Additionally, it allows redefi nition of outcomes or predictors based on continuous variables and usage of information that did not reach publication in the original research.
The primary goal of this IPD meta-analysis study was to calculate the recurrence risk of HDP. Secondarily, we aimed to show the recurrence of individual hypertensive syndromes.
Materials and methods
We performed a literature search in the electronic libraries PubMed (Medline) and Embase. Language restrictions or restrictions on publication date were not applied. . Crossreferences of the selected studies were checked to identify other studies of interest. All studies that described cohorts of women with a history of a hypertensive disorder that resulted in a delivery at any gestational age were eligible for inclusion. Inclusion was not restricted to any study design, apart from for case-control studies, where recurrence was a prerequisite. Studies that did not report recurrence of preeclampsia in the publication, but was thought to have this information in the original data, were also considered eligible. If data between studies overlapped, only the larger of the 2 studies was included. Two independent reviewers (M.F.vO. and J.L.) screened the identified articles for eligibility based on title and abstract. Discrepancies were resolved by a third reviewer (W.G.).
Data collection
For each of the eligible articles, contact information of the first, second, or last author was obtained through Medline, Embase, or the Internet. We approached the authors by email to inform them about the IPD meta-analysis project and to invite them to share their data. If authors were willing to participate, they were provided a more detailed study proposal and asked to send their original database. Variables and categories needed to be labeled adequately within the original database or in a separate data dictionary. Data of women who had a subsequent pregnancy after the hypertensive pregnancy were included. We focused on collecting demographic characteristics that included age, body mass index (BMI), cardiovascular risk factors, and the clinical syndrome of the index pregnancy. The quality of all studies that were included was evaluated with the Newcastle Ottawa Scale for cohort studies.
5
Defi nitions HDP were defi ned as GH, preeclampsia, superimposed preeclampsia, or HELLP syndrome. Non-hypertensive pregnancies with an SGA child were excluded. Chronic hypertension was not an exclusion criterion for the IPD but was in some individual studies.
Preeclampsia was defi ned as hypertension (diastolic blood pressure ≥90 mm Hg or systolic blood pressure ≥140 mm Hg on 2 occasions that were [4] [5] hours apart) in combination with proteinuria (defi ned as a positive [0.3 g/L] proteinuria dipstick test, a protein/creatinine ratio of ≥30 mg/mmol in a random sample or an urine protein excretion of ≥300 mg for 24 hrs) after 20 weeks' gestation. 13 Mild or severe preeclampsia was not separately defi ned, because only some of the studies made this distinction in their data. Women with hypertension at >20 weeks' gestation without proteinuria or a signifi cant rise in blood pressure (if a woman had known chronic hypertension) were considered to have GH. Chronic hypertension was defi ned as the presence or a history of preconceptional hypertension or detection of hypertension in the fi rst one-half of the pregnancy. De novo proteinuria or a sudden increase in proteinuria if already present, qualifi ed women with chronic hypertension for superimposed preeclampsia. 13 HELLP syndrome was defi ned by hemolysis (elevated lactate dehydrogenase levels [≥600 U/L], elevated liver enzymes by levels of aspartate transaminase or alanine transferase ≥70 U/L, and low platelets <100,000/mm).
14 HELLP syndrome in combination with hypertension was also classifi ed as preeclampsia. SGA was defi ned as birthweight <10 th percentile, according to the American College of Obstetricians and Gynecologists practice bulletin, 15 and adjusted for gestational age based on a local reference population. The exact defi nitions for the hypertensive syndromes that were used in the included studies were not retrievable for a few studies that were published as abstracts. 16, 17 Nevertheless, we presume that the authors concur about the international accepted criteria, which were described earlier.
The primary outcome was the recurrence of any HDP in the next subsequent pregnancy. Secondarily, we aimed to show the recurrence of individual hypertensive syndromes.
Statistical analysis
Most studies focused on detailed data of the subsequent pregnancy, whereas some studies registered only details of the index pregnancy. To use the data as best as possible, we combined data of the index and subsequent pregnancy for BMI, smoking, medical history, and chronic hypertension. If, for example, BMI was recorded at the time of the second pregnancy, but not at the index pregnancy, then we copied the second pregnancy BMI information.
Not all the dependent or independent variables have been registered in every database. Results therefore are accompanied with the number of cases in which the variable was registered (n). Proportions are presented as percentages of n, rather than as percentages of the total population. For descriptive analysis, we expressed continuous variables as mean with standard deviation or median with interquartile range, as appropriate. We decided not to use imputation because the pattern of systematic missing values cannot be extrapolated between databases.
Differences in outcomes between the index and subsequent pregnancy were investigated with the use of a random intercept/random effects binomial regression model for dichotomous outcomes and of a random intercept random/effects linear regression model for continuous outcomes. A random intercept was fitted per study to account for the fact that the baseline risk between studies may differ. Based on Akaike's information criterion, the random effects model was compared with a fixed effects model, and the model with the lowest Akaike's information criterion was used as the final model for analysis for that outcome. Heterogeneity across studies was assessed with the I2 measure, and the values were interpreted in the following manner: 0% indicates no observed heterogeneity; 25%, 50%, and 75% indicate low, moderate, and high heterogeneity, respectively. 18 Probability values < .05 were considered to indicate statistical significance. We have performed 3 post hoc sensitivity analyses: in one of them, we performed separate analysis for studies with < or >200 inclusions; in one of them, we excluded retrospective studies; and in one of them, we excluded studies with high or unclear risk of bias. Statistical analysis was performed with SPSS software (version 20.0; SPSS Inc, Chicago, IL) and R software (version 3.0.1; The R Foundation for Statistical Computing).
Results

Study selection
Our search of PubMed and Embase for eligible articles until August 2012 yielded 2819 non-duplicate hits. After screening title and abstract, a total of 94 articles were included. Of these articles, 6 were excluded because of overlapping databases; 39 were excluded because of failure to make contact; 14 were excluded because of unavailable data; 2 were excluded because of judgment of data as not useful by the authors; and 11 authors 5 decided not to share their data. Reasons for declining to share data included no interest in participation, still in the publication process, and a statement of "no permission to send data outside the national borders." Eventually, the IPD of 22 articles were included in this IPD meta-analysis (Figure 1) . The combined database comprised a total of 99,415 women. An overview of the study characteristics of the included studies can be seen in Table 1 . Most of the women were included from 3 registry-based studies that lack demographic and clinical detail. 31, 32, 38 Two authors of included registry-based studies were unable to provide the original data but offered to perform a new data-extraction. 22, 38 They used the criteria from the initial study to create an extended and more recent database. Eight prospective trials were included that investigated the effects of aspirin, 19, 21, 24, 27, 37 low-molecular-weight (LMW) heparin, 25, 27, 37 vitamins, 23, 36 and close surveillance 37 on the recurrence of hypertensive disease and maternal and fetal outcome. Quality characteristics of all included studies that used the Newcastle Ottawa Scale 12 are shown in Figure 2 . To test for selection bias in the process of inclusion of IPD, a meta-analysis of recurrence rates in literature was performed. We used the originally included 88 articles (leaving out the overlapping datasets). Where available we used IPD (22 articles). Another 24 articles had to be excluded because applicable recurrence rates were not published. Of these articles, only IPD that did not reach publication would have been useful, for example in specific subgroups. Regarding gestational hypertensive disorders, 64 articles that encompassed a total of 152,213 women with an HDP reported on 27,558 recurrences, which resulted in a recurrence rate of 18.1% (95% CI, 17.9 -18.3). The range of recurrence rates in the cohorts was 6-83%. 29 Recurrence rates of individual syndromes of HDP were not reported very consistently over studies. References of the 64 articles in this meta-analysis are available in the Appendix (Supplementary Table) .
The baseline characteristics of the 99,415 women who were included in the IPD are shown in Table 2 . The occurrence of major maternal complications (such as pulmonary edema or maternal death) was recorded too sporadically to be reported. Figure 3 gives a more detailed overview of recurrence of the separate syndromes of hypertensive disorders and the effects of prematurity on recurrence according to hypertensive syndrome and gestational age at onset at the index pregnancy. Sensitivity analyses showed comparable recurrence rates when studies with unclear or high risk of bias were excluded from analysis and showed the same range of recurrence rates when discriminating studies by size and study design (data not shown).
The clinical syndrome in the index and subsequent pregnancy
To assess differences between the clinical hypertensive syndrome in the index and subsequent pregnancy in women with recurrence, we compared the variables as shown in Table 3 . Heterogeneity was high for intravenous anticonvulsive medication, cesarean delivery, and premature delivery at <34 and <37 weeks' gestation; was moderate for oral antihypertensive medication and premature delivery at <28 weeks' gestation; was low for maximum diastolic blood pressure, SGA < p10, and was absent for the other outcomes. The maximum diastolic blood pressure was, on average, lower in the subsequent pregnancy; proteinuria >300 mg/24 hours occurred less often, and oral antihypertensive or intravenous anticonvulsive medication was necessary less frequently. The subsequent pregnancy was complicated less often by a cesarean delivery, delivery of an SGA child, premature delivery, and perinatal death. Continuous data are presented as means (SD); age, BMI and gestational age in median (IQR) Proportions are shown as n (% of N) * Number of women with available information † Percentages sum up to more than 100% because of overlapping of disorders Similar to the sensitivity analyses for recurrence rate, the analyses showed comparable associations between the index and subsequent pregnancy after exclusion of studies with unclear or high risk of bias and showed the same range of associations when discriminating studies by size and study design (data not shown).
Chronic hypertension after pregnancy
Chronic hypertension that occurred after pregnancy was reported in 5 studies. [28] [29] [30] 34, 35 After exclusion of chronic hypertension before pregnancy, we included 581 women who were normotensive before pregnancy, who experienced an HDP, and in whom chronic hypertension after pregnancy was registered. Of these, 236 women (41%) had recurrence of a hypertensive disorder in the next pregnancy. Women with recurrence experienced chronic hypertension more often than women without recurrence (28.4% vs 9.6%; OR, 4.2; 95% CI, 2.6 -6.7). 
Comment
This IPD meta-analysis explored the recurrence risk and predictors for recurrence of HDP. The creation of this large combined database produced an opportunity to calculate an overall recurrence rate of HDP and to explore the role of individual risk factors. Some of the bias that was introduced in single cohort studies based on patient selection criteria and methods could be reduced. The diversity of inclusion criteria of the included databases reflects the diverse world population.
Main fi ndings
The recurrence rate of an HDP (any type) is 20.7% (95% CI, 20.4e20.9). Concomitant HELLP syndrome or delivery of an SGA child increases recurrence of HDP. Also, decreasing gestational age at delivery in the index pregnancy increases both the chance of having recurrence and the chance to deliver prematurely again. Multiple pregnancy at the index pregnancy, as a risk factor for the occurrence of HDP, is protective for recurrence. The use of LMW heparin was not protective for recurrence in our data, but the numbers are too small to draw conclusions. If the hypertensive disorder recurred, it was in general milder, regarding most of the investigated variables. Women who were normotensive before pregnancy and who experienced recurrence of a hypertensive disorder had a 4 times increased risk of the development of chronic hypertension after pregnancy.
Strengths and weaknesses
Undertaking this study was not without challenges. Study selection was impaired and prolonged by difficulties in contacting authors of the original articles. Eligible studies date back to the eighties, which caused data to be lost, authors to be retired, and accurate contact information to be absent. We were able to include 22 of the 88 (25%) eligible articles. Unfortunately, several important studies were not included. The inclusion rate is adequate compared with other published IPD meta-analyses with inclusion rates of 12-24% 40, 41 ; 1 study included 6 of 10 eligible studies that added up to an inclusion rate of 60%. 41 The number of IPD in our study on the other hand was much higher than in other IPDs, mostly containing several thousands of participants. [40] [41] [42] The reason for this is our inclusion of nationwide registry based studies. Our combined database includes 99,415 women with a subsequent pregnancy, which is 69% of the 143,659 women who could be included in our regular meta-analysis of the 88 eligible studies. In comparison with the meta-analysis of these 88 studies, the recurrence rates differ statistically: 20.7% vs 18.1%; OR, 1.18 (95% CI, 1.15 -1.20; P < .001), which suggests that some bias has occurred in the inclusion of data in our IPD. Thus, this IPD database may not be a completely representative cohort of the originally eligible studies, but it is close.
Another limitation of this study is the fact that we merged data that were obtained from very different study designs, settings, and populations, which accounts for the enormous range of recurrence rates of 6-83%. The upper bound of this range originates from a study with a very small and extremely high-risk population.29 It is unsurprising that heterogeneity across studies, which were assessed with the I2 measure, was high for some of our results. The missing data that inevitably originated from merging databases challenged the statistical analysis. One of the methods that we used to overcome the problem of missing data was the merging of information on BMI, smoking, medical history, and chronic hypertension between the 2 consecutive pregnancies. Although 5 these characteristics can vary, we do think that, on average, it gives a good indication of risk profi le for the individual woman.
Furthermore, we included prophylactic trials in this IPD meta-analysis: 7 randomized controlled trials that investigated the effect of aspirin vs placebo, 19, 21, 24 vitamins vs placebo, 23, 36 LMW-heparin plus aspirin vs aspirin alone, 27 or LMW-heparin in thrombophilic women vs no treatment in non-thrombophilic women. 37 The inclusion of these studies might be problematic when the treatments that were investigated in the different studies were effective in the reduction of hypertensive disorder recurrence. Two trials found a signifi cant treatment effect. One trial found a signifi cant reduction of recurrence in those treated with LMW heparin plus aspirin compared with aspirin alone, 27 but the numbers were very small (1 and 7 women experienced preeclampsia in the next pregnancy). The same applies for a trial that reported a signifi cant effect of vitamin use compared with placebo. 23 In addition, another vitamins trial shows conflicting results. 36 Given the small sample sizes of the trials with a signifi cant treatment effect and given these unclear relations to the recurrence of HDP, we do not expect that the inclusion of these studies hampers the generalizability of the results of this IPD meta-analysis in any way.
Variables that were registered infrequently limited the analyses of the data. The percentages shown in Table 2 therefore could be diffi cult to interpret. HELLP syndrome was recorded present in only 512 women (0.5%of all included women), and SGA accompanied a HDP in 6448 cases (7%). This is unfortunate because they are parts of the placental syndrome. The same applies for the inclusion of multiples pregnancy in the index pregnancy of 0.5%, which was an exclusion criterion in some included studies. The presence of thrombophilia also requires an explanation. If registered, thrombophilia was present in 41%. The inclusion of studies with thrombophilia as one of the inclusion criteria resulted in this high percentage. We do not think this will act as bias because it is documented in only 0.5% of the total cohort.
Another problem is reporting bias. Eclampsia was reported quite often (8% in 26.665 women in whom this complication was registered) in the index pregnancy. It is understandable that, if eclampsia occurred, it is more likely to be registered than when it did not occur.
Sensitivity analysis, in which we discriminated studies by study design and size, showed some discordant results. This was mainly due to loss of power: the analyses of small studies and prospective studies separately comprised 972 and 1955 of the 915,415 inclusions, respectively (1% and 2%). In contrast, the overall analysis was dominated mainly by 3 large retrospective studies. 31, 32, 38 Also, the results were diffi cult to interpret because most prospective studies did not register clinical details of the index pregnancy. The sensitivity analysis that included only low risk of bias studies had results that were comparable with the overall results, mainly because only 3 small studies were excluded from analysis. 26, 27, 29 Counseling Counseling couples about the chance of recurrence is important. This IPD meta-analysis did not include women who refrained from a subsequent pregnancy. Three included databases contained information about the reason for not engaging in a subsequent pregnancy. 30, 34, 35 Of 471 women, 140 (29%) refrained from a next pregnancy because of high perceived risk. This does not comply with the 21% recurrence risk and the fact that HDP recur in a milder form. The knowledge from this IPD meta-analysis can be used in counseling in the future.
In conclusion, interpretation of previous data of individual cohort studies was hampered by many sources of bias. IPD meta-analysis is a methods and logistically challenging approach. However, despite all the challenges and limitations stated earlier, the results are based on the largest database regarding recurrence of HDP so far. The opportunities of aggregated datasets are of paramount importance, because they allow the calculation of overall recurrence rates and also identify more accurately the role of individual risk factors on an individual level. The present IPD meta-analysis helped to create knowledge that can be included comprehensively in the counseling of couples after they have experienced HDP.
